CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

My Organizations' Clinical Trials

Showing 25 of 36 entries

View as:

RDEA3170 Monotherapy in Subjects With Gout

Phase: N/A Priority: Normal

NCT ID: NCT01927198 Org: User:

Start: 08/31/13 End: 07/31/14 Due: 07/31/15

Naïve HIV POC Monotherapy Trial

Phase: N/A Priority: Normal

NCT ID: NCT00617526 Org: User:

Start: 01/31/08 End: 08/31/08 Due: 08/31/09

Metformin and Furosemide Drug-Drug Interaction Study

Phase: N/A Priority: Normal

NCT ID: NCT02028689 Org: User:

Start: 10/31/13 End: 01/31/14 Due: 01/31/15

Lesinurad Interaction Study With Ranitidine

Phase: N/A Priority: Normal

NCT ID: NCT01908257 Org: User:

Start: 07/31/13 End: 11/30/13 Due: 11/30/14

RDEA3170 and Febuxostat Combination Study in Gout Subjects

Phase: N/A Priority: Normal

NCT ID: NCT02246673 Org: User:

Start: 10/31/14 End: 02/29/16 Due: 02/28/17

RDEA3170 Bioavailability Study

Phase: N/A Priority: Normal

NCT ID: NCT02336594 Org: User:

Start: 11/30/14 End: 03/31/15 Due: 03/31/16

NSAID Drug Interaction Study

Phase: N/A Priority: Normal

NCT ID: NCT01884272 Org: User:

Start: 06/30/13 End: 10/31/13 Due: 10/31/14

Lesinurad and Allopurinol Combination Extension Study in Gout

Phase: N/A Priority: Normal

NCT ID: NCT01808131 Org: User:

Start: 02/28/13 End: 11/30/16 Due: 11/30/17

Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors

Phase: N/A Priority: Normal

NCT ID: NCT01508702 Org: User:

Start: 01/31/12 End: 11/30/13 Due: 11/30/14

Lesinurad and Febuxostat Combination Extension Study in Gout

Phase: N/A Priority: Normal

NCT ID: NCT01808144 Org: User:

Start: 03/01/13 End: 10/06/16 Due: 10/06/17

RDEA3170 PK/PD Study

Phase: N/A Priority: Normal

NCT ID: NCT02608710 Org: User:

Start: 11/30/15 End: 04/30/16 Due: 04/30/17

Mild, Moderate and Severe Renal Impairment Study

Phase: N/A Priority: Normal

NCT ID: NCT02219516 Org: User:

Start: 08/01/14 End: 05/13/16 Due: 05/13/17

RDEA3170 and Allopurinol Combination Study in Gout Subjects

Phase: N/A Priority: Normal

NCT ID: NCT02279641 Org: User:

Start: 11/01/14 End: 09/11/15 Due: 09/11/16

Allopurinol Outcome Study

Phase: N/A Priority: Normal

NCT ID: NCT01391325 Org: User:

Start: 07/31/11 End: 03/31/13 Due: 03/31/14

Antacid Interaction Study

Phase: N/A Priority: Normal

NCT ID: NCT01982201 Org: User:

Start: 11/30/13 End: 03/31/14 Due: 03/31/15

RDEA3170 AME Study

Phase: N/A Priority: Normal

NCT ID: NCT01910506 Org: User:

Start: 08/31/13 End: 11/30/13 Due: 11/30/14

Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects

Phase: N/A Priority: Normal

NCT ID: NCT02498652 Org: User:

Start: 07/28/15 End: 06/02/16 Due: 06/02/17

Lesinurad Tablet Relative Bioavailability

Phase: N/A Priority: Normal

NCT ID: NCT01986556 Org: User:

Start: 11/30/13 End: 05/31/14 Due: 05/31/15

Allopurinol Combination Study

Phase: N/A Priority: Normal

NCT ID: NCT01001338 Org: User:

Start: 10/31/09 End: 08/31/16 Due: 08/31/17

RDEA3170 and Febuxostat Drug Interaction Study

Phase: N/A Priority: Normal

NCT ID: NCT01883167 Org: User:

Start: 06/30/13 End: 12/31/13 Due: 12/31/14

Bioavailability of Lesinurad and Intravenous [14C]Lesinurad

Phase: N/A Priority: Normal

NCT ID: NCT02039700 Org: User:

Start: 01/31/14 End: 04/30/14 Due: 04/30/15

Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence.

Phase: N/A Priority: Normal

NCT ID: NCT03272425 Org: User:

Start: 08/14/17 End: 10/04/17 Due: 10/04/18

Combining Lesinurad With Allopurinol in Inadequate Responders

Phase: N/A Priority: Normal

NCT ID: NCT01493531 Org: User:

Start: 12/31/11 End: 07/31/14 Due: 07/31/15

Single and Multiple Dose Study in Japanese

Phase: N/A Priority: Normal

NCT ID: NCT01744379 Org: User:

Start: 12/31/12 End: 05/31/13 Due: 05/31/14

Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability

Phase: N/A Priority: Normal

NCT ID: NCT02581553 Org: User:

Start: 10/31/15 End: 08/31/16 Due: 08/31/17

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
RDEA3170 Monotherapy in Subjects With Gout	NCT01927198	Ardea Biosciences, Inc.	user2@example.com	None	2013-08-31	2014-07-31	2015-07-31	-	-	2025-07-14
Naïve HIV POC Monotherapy Trial	NCT00617526	Ardea Biosciences, Inc.	user2@example.com	None	2008-01-31	2008-08-31	2009-08-31	-	-	2025-07-14
Metformin and Furosemide Drug-Drug Interaction Study	NCT02028689	Ardea Biosciences, Inc.	user2@example.com	None	2013-10-31	2014-01-31	2015-01-31	-	-	2025-07-14
Lesinurad Interaction Study With Ranitidine	NCT01908257	Ardea Biosciences, Inc.	user2@example.com	None	2013-07-31	2013-11-30	2014-11-30	-	-	2025-07-14
RDEA3170 and Febuxostat Combination Study in Gout Subjects	NCT02246673	Ardea Biosciences, Inc.	user2@example.com	None	2014-10-31	2016-02-29	2017-02-28	-	-	2025-07-14
RDEA3170 Bioavailability Study	NCT02336594	Ardea Biosciences, Inc.	user2@example.com	None	2014-11-30	2015-03-31	2016-03-31	-	-	2025-07-14
NSAID Drug Interaction Study	NCT01884272	Ardea Biosciences, Inc.	user2@example.com	None	2013-06-30	2013-10-31	2014-10-31	-	-	2025-07-14
Lesinurad and Allopurinol Combination Extension Study in Gout	NCT01808131	Ardea Biosciences, Inc.	user2@example.com	None	2013-02-28	2016-11-30	2017-11-30	-	-	2025-07-14
Lesinurad Monotherapy in Gout Subjects Intolerant to Xanthine Oxidase Inhibitors	NCT01508702	Ardea Biosciences, Inc.	user2@example.com	None	2012-01-31	2013-11-30	2014-11-30	-	-	2025-07-14
Lesinurad and Febuxostat Combination Extension Study in Gout	NCT01808144	Ardea Biosciences, Inc.	user2@example.com	None	2013-03-01	2016-10-06	2017-10-06	-	-	2025-07-14
RDEA3170 PK/PD Study	NCT02608710	Ardea Biosciences, Inc.	user2@example.com	None	2015-11-30	2016-04-30	2017-04-30	-	-	2025-07-14
Mild, Moderate and Severe Renal Impairment Study	NCT02219516	Ardea Biosciences, Inc.	user2@example.com	None	2014-08-01	2016-05-13	2017-05-13	-	-	2025-07-14
RDEA3170 and Allopurinol Combination Study in Gout Subjects	NCT02279641	Ardea Biosciences, Inc.	user2@example.com	None	2014-11-01	2015-09-11	2016-09-11	-	-	2025-07-14
Allopurinol Outcome Study	NCT01391325	Ardea Biosciences, Inc.	user2@example.com	None	2011-07-31	2013-03-31	2014-03-31	-	-	2025-07-14
Antacid Interaction Study	NCT01982201	Ardea Biosciences, Inc.	user2@example.com	None	2013-11-30	2014-03-31	2015-03-31	-	-	2025-07-14
RDEA3170 AME Study	NCT01910506	Ardea Biosciences, Inc.	user2@example.com	None	2013-08-31	2013-11-30	2014-11-30	-	-	2025-07-14
Phase 2a RDEA3170 and Allopurinol Combination Study in Gout Subjects	NCT02498652	Ardea Biosciences, Inc.	user2@example.com	None	2015-07-28	2016-06-02	2017-06-02	-	-	2025-07-14
Lesinurad Tablet Relative Bioavailability	NCT01986556	Ardea Biosciences, Inc.	user2@example.com	None	2013-11-30	2014-05-31	2015-05-31	-	-	2025-07-14
Allopurinol Combination Study	NCT01001338	Ardea Biosciences, Inc.	user2@example.com	None	2009-10-31	2016-08-31	2017-08-31	-	-	2025-07-14
RDEA3170 and Febuxostat Drug Interaction Study	NCT01883167	Ardea Biosciences, Inc.	user2@example.com	None	2013-06-30	2013-12-31	2014-12-31	-	-	2025-07-14
Bioavailability of Lesinurad and Intravenous [14C]Lesinurad	NCT02039700	Ardea Biosciences, Inc.	user2@example.com	None	2014-01-31	2014-04-30	2015-04-30	-	-	2025-07-14
Lesinurad/Allopurinol 200/300 Fixed-Dose Combination (FDC) Tablets Bioequivalence.	NCT03272425	Ardea Biosciences, Inc.	user2@example.com	None	2017-08-14	2017-10-04	2018-10-04	-	-	2025-07-14
Combining Lesinurad With Allopurinol in Inadequate Responders	NCT01493531	Ardea Biosciences, Inc.	user2@example.com	None	2011-12-31	2014-07-31	2015-07-31	-	-	2025-07-14
Single and Multiple Dose Study in Japanese	NCT01744379	Ardea Biosciences, Inc.	user2@example.com	None	2012-12-31	2013-05-31	2014-05-31	-	-	2025-07-14
Lesinurad/Allopurinol 200/300 FDC Tablets Bioavailability	NCT02581553	Ardea Biosciences, Inc.	user2@example.com	None	2015-10-31	2016-08-31	2017-08-31	-	-	2025-07-14

Compliance Rate

My Organizations' Clinical Trials

Appearance